Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research interest is in improving outcomes for patients with glioblastoma by combining radiotherapy with drug therapies that target the DNA damage response. His laboratory also studies the mechanisms responsible for treatment resistance in GBM including a novel link between radiation response and the invasive phenotype of these tumours.
He is Chief Investigator for a portfolio of early phase clinical trials evaluating the PARP inhibitor olaparib and the ATM inhibitor AZD1390 in combination with radiotherapy and/or chemotherapy in the treatment of glioblastoma, and is working with other UK investigators to build novel clinical trial platforms including BRAIN-MATRIX and the CONCORDE study in non-small cell lung cancer.
From 2016 to 2019 he was Chair of the UK’s Clinical and Translational Radiotherapy Research Working Group (CTRad) and he established the Radiotherapy-Drug Combinations Consortium (RaDCom), a joint initiative between Cancer Research UK and the National Cancer Research Institute. Currently a Board Member of the European Association for Neuro-Oncology (EANO), he sits on the Radiobiology Committee of the European Society for Therapeutic Radiation Oncology (ESTRO) and is Chair of the Scottish Radiotherapy Research Forum (ScoRRF).